VIVA BIOTECH: UPDATE ANNOUNCEMENTADOPTION OF THE VIVA SHANGHAI PHASE I SHARE OPTION SCHEMEAND THE VIVA SHANGHAI PHASE II SHARE OPTION SCHEME; ANDUPDATE ON GRANT OF SHARE OPTIONS TO CERTAIN PARTICIPANTS
VIVA BIOTECH: (1) PROPOSED ADOPTION OF THE VIVA SHANGHAI PHASE I SHARE OPTION SCHEME AND THE VIVA SHANGHAI PHASE II SHARE OPTION SCHEME; AND (2) PROPOSED CONDITIONAL GRANT OF SHARE OPTIONS TO CONNECTED PERSONS AND OTHER PARTICIPANTS
VIVA BIOTECH: COMPLETION OF MAJOR TRANSACTION IN RELATION TOTHE DEEMED DISPOSAL OF EQUITY INTEREST IN A SUBSIDIARYANDAUTOMATIC CONVERSION OF CONVERTIBLE BONDS
VIVA BIOTECH: COMPLETION OF THE CSRC POST-ISSUE FILING IN RELATION TO THE ISSUE OF CONVERTIBLE BONDS
VIVA BIOTECH: COMPLETION OF ISSUE OF CONVERTIBLE BONDS UNDER GENERAL MANDATE
VIVA BIOTECH: ISSUE OF CONVERTIBLE BONDS UNDER GENERAL MANDATE
Viva Biotech Holdings: CANCELLATION AND GRANT OF SHARE OPTIONS
Viva Biotech Holdings: RESET OF CONVERSION PRICE OF THE 2.50 PER CENT. GUARANTEED CONVERTIBLE BONDS DUE 2025 (THE "BONDS", STOCK CODE: 40144)
Viva Biotech Holdings: GRANT OF SHARE OPTIONS
Viva Biotech Holdings: SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO GRANT OF SHARE OPTIONS
Viva Biotech Holdings: GRANT OF SHARE OPTIONS
Viva Biotech Holdings: COMPLETION OF THE ACQUISITION OF THE ENTIRE EQUITY INTEREST IN SYNTHESIS MED CHEM (HONG KONG) LIMITED INVOLVING ISSUE OF CONSIDERATION SHARES UNDER GENERAL MANDATE
Viva Biotech Holdings: MAJOR TRANSACTION IN RELATION TO THE ACQUISITION OF THE ENTIRE ISSUED SHARE CAPITAL IN SYNTHESIS MED CHEM (HONG KONG) LIMITED
Viva Biotech Holdings: PROPOSED REFRESHMENT OF GENERAL MANDATE AND NOTICE OF EXTRAORDINARY GENERAL MEETING
Viva Biotech Holdings: MAJOR TRANSACTION AMENDMENT OF THE SHARE TRANSFER AGREEMENT
Viva Biotech Holdings: MAJOR TRANSACTION-GRANT OF WAIVER UNDER FROM STRICT COMPLIANCE WITH RULE 14.41(A) OF THE LISTING RULES,DELAY IN DISPATCH OF CIRCULAR AND TRANSACTION UPDATE
Viva Biotech Holdings: COMPLETION OF THE ISSUE OF US$280 MILLION 1.00 PER CENT GUARANTEED CONVERTIBLE BONDS DUE 2025
Viva Biotech Holdings: MAJOR TRANSACTION UPDATE ON POTENTIAL ISSUE OF CONSIDERATION SHARES
Viva Biotech Holdings: PROPOSED ISSUE OF US$280 MILLION 1.00% GUARANTEED CONVERTIBLE BONDS DUE 2025
Viva Biotech Holdings: MAJOR TRANSACTION FURTHER DELAY IN DISPATCH OF CIRCULAR, APPLICATION FOR A WAIVER UNDER RULE 14.41(A) OF THE LISTING RULES AND EXTENSION OF THE LONGSTOP DATE
No Data
No Data